Tirzepic GLP-1 + GIP

Structure and Receptor Pharmacology

Tirzepic GLP-1 + GIP is a synthetic 39-amino acid peptide designed as a dual agonist of GLP-1R and GIPR. The base sequence derives from native GIP(1-42) with modifications enabling cross-activation of the GLP-1 receptor. Key amino acid substitutions include position 2 (Aib instead of Ala, conferring resistance to DPP-4 cleavage), while a C20 diacyl fatty acid conjugated to Lys20 via a glutamic acid linker enables plasma albumin binding.

In radioligand binding studies (in vitro), Tirzepic demonstrates agonist activity at both incretin receptors: nanomolar affinity for GIPR (comparable to native GIP) and sub-nanomolar affinity for GLP-1R. This dual binding profile is unique among synthetic peptide analogs and results from a sequence design that preserves structural motifs recognized by both the GIPR and GLP-1R extracellular domains (ECD). The peptide has a molecular weight of approximately 4813 Da and an isoelectric point in the range of 5.0 to 5.5.

Mechanism of Dual Receptor Activation

Both target receptors of Tirzepic, GLP-1R and GIPR, belong to the class B1 G protein-coupled receptor (GPCR) family and share a common Gs/cAMP effector pathway. Upon agonist binding to either receptor, adenylyl cyclase is activated, increasing intracellular cAMP levels and triggering PKA and Epac2 activation. However, despite an identical effector mechanism, the tissue expression profiles of the two receptors differ substantially.

GIPR is highly expressed in pancreatic beta cells, bone tissue, adipocytes, and the central nervous system. GLP-1R, on the other hand, is expressed in pancreatic beta cells but also in the heart, kidneys, lungs, and multiple brain structures (nucleus tractus solitarius, area postrema, hypothalamus). This complementary tissue distribution means that a dual agonist activates the cAMP pathway in a broader spectrum of cells compared to a monoagonist selective for a single receptor.

In in vitro experiments on isolated pancreatic beta cells (INS-1E cell line), simultaneous stimulation of GLP-1R and GIPR was shown to produce additive and, under certain conditions, synergistic increases in intracellular cAMP compared to single-receptor activation. The mechanism behind this synergy is not fully elucidated but may result from differences in desensitization kinetics: GIPR undergoes slower beta-arrestin-mediated internalization than GLP-1R, leading to prolonged Gs signaling from one of the two activated receptors.

Research Overview

Pharmacology and physiology of incretin hormones

Campbell JE and Drucker DJ (2013) ^[1] published a comprehensive review characterizing the pharmacology, physiology, and mechanisms of action of incretin hormones. The authors described in detail the structure of GLP-1R and GIPR as class B1 GPCRs, their tissue distribution, and the signaling pathways activated upon ligand binding (Gs/cAMP/PKA, Epac2, beta-arrestin). The paper discusses the proteolytic degradation kinetics of incretins by DPP-4 and chemical strategies used to design enzyme-resistant analogs.

GIP and GLP-1 biology: receptor complementarity

Seino Y, Fukushima M, and Yabe D (2010) ^[2] presented a comparative analysis of GIP and GLP-1 biology, focusing on differences in receptor tissue expression and consequences for cellular signaling. The study demonstrated that GIPR predominates in bone tissue and adipocytes, while GLP-1R shows broader distribution including the heart, kidneys, and CNS structures.

cAMP signaling in the context of GIPR activation

Ehses JA et al. (2002) ^[3] investigated the mechanism of cAMP/PKA cascade activation following GIPR stimulation in isolated pancreatic beta cells (INS-1 cell line). Using FRET probes, the authors demonstrated real-time kinetics of cAMP concentration increase after native GIP administration.

Structural basis of GIPR and GLP-1R selectivity

Yaqub T et al. (2010) ^[4] performed site-directed mutagenesis analysis of the GIPR ECD domain, identifying amino acid residues critical for recognition of the N-terminus of native GIP peptide. These data have direct implications for understanding how a single peptide sequence (as in dual agonists) can simultaneously activate both incretin receptors.

References

1. Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." Cell Metabolism. 2013;17(6):819-837.
2. Seino Y, Fukushima M, Yabe D. "GIP and GLP-1, the two incretin hormones: Similarities and differences." Journal of Diabetes Investigation. 2010;1(1-2):8-23.
3. Ehses JA, et al. "Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway." Journal of Biological Chemistry. 2002;277(40):37088-37097.
4. Yaqub T, et al. "Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand." Molecular Pharmacology. 2010;77(4):547-558.

Comparison with Mono- and Triple Agonists

Pharmacological profile comparison of the dual agonist Tirzepic with the monoagonist Sematic GLP-1 and the triple agonist Retatric Triple G:

The dual profile of Tirzepic enables cAMP activation in tissues with low GLP-1R expression but high GIPR expression (e.g., bone tissue). At the same time, compared to the triple agonist Retatric Triple G, the absence of GCGR activation means no direct cAMP stimulation in hepatocytes, where GCGR shows predominant expression.

Stability and Storage

Tirzepic is supplied as a lyophilized powder with purity above 98% (RP-HPLC). In dry form, store the peptide at -20°C to -80°C (stability at least 24 months). After reconstitution in sterile water, store the solution at 2-8°C and use within 30 days. The C20 diacyl fatty acid acylation provides additional hydrophobic stabilization in aqueous solution. Avoid repeated freeze-thaw cycles.

Related Research Materials

A detailed description of GLP-1 and GIP peptide signaling mechanisms, their pharmacokinetics, and the role of DPP-4 enzyme in incretin degradation is available in our knowledge base article GLP-1 and GIP: Incretin Signaling Mechanisms.

Intended Use

This product is a chemical raw material intended exclusively for in vitro research, scientific, and analytical applications. It is not intended for human or veterinary use, including for diagnostic, therapeutic, prophylactic, or nutritional purposes.

Handling

• Work in laboratory conditions consistent with Good Laboratory Practice (GLP) principles.
• Use appropriate personal protective equipment: nitrile gloves, safety goggles, lab coat.
• Avoid inhalation of dust and contact with skin or mucous membranes.
• Work in a well-ventilated area.

Regulatory Classification

This product is not classified as a hazardous substance under CLP Regulation (EC) No 1272/2008. It is offered as a chemical reagent within the framework of applicable European Union chemical substances regulations (REACH, CLP). It does not constitute a medicinal product, dietary supplement, medical device, or cosmetic within the meaning of applicable laws.

Disposal

Unused material should be disposed of in accordance with local regulations on chemical waste. Under laboratory conditions: neutralize and dispose with laboratory waste streams. Do not discharge into sewage systems.

Regulatory Information

This product is offered in accordance with applicable European Union regulations on chemical substances (REACH, CLP) and Polish law governing the trade of chemical reagents and research materials. Full terms of sale and product classification are set out in the Terms of Service.

By placing an order, the Customer confirms having read the above information and accepts the provisions of the Terms.

Safety Contact

For questions regarding handling or regulatory information: [email protected].